Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunoadsorption patients with multiple sclerosis: an open-label pilot study.

A Moldenhauer1, J Haas, C Wäscher

  • 1Charité--Universitätsmedizin Berlin, Germany. anja.moldenhauer@charite.de

European Journal of Clinical Investigation
|August 17, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cyclooxygenase-2 expression as a prognostic factor in pediatric classical Hodgkin lymphoma.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2020
Same author

Malignant renal obstruction without dilatation.

Acute medicine·2019
Same author

Efficacy and safety of a new intravenous immunoglobulin (Panzyga<sup>®</sup> ) in chronic immune thrombocytopenia.

Transfusion medicine (Oxford, England)·2019
Same author

IL-28B rs12979860 polymorphism affect the course of chronic hepatitis and the development of HCC in Egyptian patients with hepatitis C type 4.

British journal of biomedical science·2018
Same author

Improvement of the developmental competence of canine oocyte using caffeine supplementation during IVM at different maturation time.

Zygote (Cambridge, England)·2018
Same author

Distinct recovery of copper and aluminum from waste electric wires using a roll-type electrostatic separator.

Waste management (New York, N.Y.)·2018
Same journal

Pacemaker Status and 5-Year Mortality After TAVI: A Sex-Specific Analysis.

European journal of clinical investigation·2026
Same journal

Causal Effects of Time-Varying Treatments: The G-Formula.

European journal of clinical investigation·2026
Same journal

Improving Scientific Research: Renegotiated Principles of Science, Proposals, Failures, and Successes.

European journal of clinical investigation·2026
Same journal

Beta-Blockers After Myocardial Infarction With Preserved and Mildly Reduced Ejection Fraction: A Meta-Analysis With Trial Sequential Analysis.

European journal of clinical investigation·2026
Same journal

Prognostic Role of Serum Albumin Levels in Elderly Patients With Non-Valvular Atrial Fibrillation.

European journal of clinical investigation·2026
Same journal

Circulating Human Epididymis Protein 4 Predicts 10-Year Mortality and Major Adverse Cardiovascular Events in Patients With Peripheral Artery Disease.

European journal of clinical investigation·2026
See all related articles

Immunoadsorption (IA) may help slow multiple sclerosis (MS) progression by removing myelin-specific antibodies. While IA showed benefits in EDSS scores, quality of life and MRI lesions remained stable.

Area of Science:

  • Neuroimmunology
  • Neurology
  • Biomedical Engineering

Background:

  • Immunoadsorption (IA) is an occasional treatment for acute multiple sclerosis (MS) relapses.
  • This study investigated IA's efficacy in secondary progressive MS (SPMS) and relapsing-remitting MS (RRMS).

Purpose of the Study:

  • To evaluate the potential benefits of IA in patients with SPMS and RRMS.
  • To assess IA's impact on disease progression and patient-reported outcomes.

Main Methods:

  • 12 patients with SPMS/RRMS and significant disability (EDSS 4.5-7) received IA treatments weekly.
  • Primary outcomes included changes in Expanded Disability Status Scale (EDSS) and MS Functional Composite (MSFC) scores over 12 months.
  • Secondary outcomes included quality of life and MRI lesion changes.

Related Experiment Videos

Main Results:

  • A significant reduction in EDSS change was observed post-IA, though this effect reversed three months after treatment cessation.
  • Ten out of 12 patients remained stable during the first year, with no significant changes in MSFC scores.
  • No significant changes were noted in MRI lesions or quality of life.

Conclusions:

  • IA, by removing immunoglobulins and myelin-specific antibodies, appears to delay MS progression as measured by EDSS, MSFC, and MRI.
  • Patient quality of life was not negatively impacted by the IA treatment.